Format

Send to

Choose Destination
Am J Respir Crit Care Med. 2015 Aug 1;192(3):283-94. doi: 10.1164/rccm.201504-0756UP.

Update in Lung Cancer 2014.

Author information

1
1 Division of Computational Biomedicine, Boston University School of Medicine, Boston, Massachusetts.
2
2 Department of Medicine, Columbia University Medical Center, New York, New York; and.
3
3 Division of Pulmonary, Critical Care, and Sleep Medicine, Icahn School of Medicine at Mount Sinai, New York, New York.

Abstract

In the past 2 years, lung cancer research and clinical care have advanced significantly. Advancements in the field have improved outcomes and promise to lead to further reductions in deaths from lung cancer, the leading cause of cancer death worldwide. These advances include identification of new molecular targets for personalized targeted therapy, validation of molecular signatures of lung cancer risk in smokers, progress in lung tumor immunotherapy, and implementation of population-based lung cancer screening with chest computed tomography in the United States. In this review, we highlight recent research in these areas and challenges for the future.

KEYWORDS:

biomarkers; chest computed tomography screening; lung cancer; lung immunotherapy; targeted therapy

PMID:
26230235
PMCID:
PMC4584253
DOI:
10.1164/rccm.201504-0756UP
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Atypon Icon for PubMed Central
Loading ...
Support Center